Furthermore, SV2A PET measures were linked to amyloid and tau pathologies, glucose hypometabolism and cognitive decline across diverse populations, including young adults, cognitively normal individuals and cognitively impaired AD patients.73, 74. This evidence concerns the gene MAPT and Alzheimer disease.